Lung Surfactant Protein B Peptide Mimics Interact with the Human ACE2 Receptor
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241310837 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Alan J Waring und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA. Hauptthemen laut MEDLINE: COVID-19, Pulmonary Surfactants. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
Abstract (Originalsprache)
Lung surfactant is a complex mixture of phospholipids and surfactant proteins that is produced in alveolar type 2 cells. It prevents lung collapse by reducing surface tension and is involved in innate immunity. Exogenous animal-derived and, more recently, synthetic lung surfactant has shown clinical efficacy in surfactant-deficient premature infants and in critically ill patients with acute respiratory distress syndrome (ARDS), such as those with severe COVID-19 disease. COVID-19 pneumonia is initiated by the binding of the viral receptor-binding domain (RBD) of SARS-CoV-2 to the cellular receptor angiotensin-converting enzyme 2 (ACE2). Inflammation and tissue damage then lead to loss and dysfunction of surface activity that can be relieved by treatment with an exogenous lung surfactant. Surfactant protein B (SP-B) is pivotal for surfactant activity and has anti-inflammatory effects. Here, we study the binding of two synthetic SP-B peptide mimics, Super Mini-B (SMB) and B-YL, to a recombinant human ACE2 receptor protein construct using molecular docking and surface plasmon resonance (SPR) to evaluate their potential as antiviral drugs. The SPR measurements confirmed that both the SMB and B-YL peptides bind to the rhACE2 receptor with affinities like that of the viral RBD–ACE2 complex. These findings suggest that synthetic lung surfactant peptide mimics can act as competitive inhibitors of the binding of viral RBD to the ACE2 receptor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA 90502, USA.
- Materials and Process Simulation Center, California Institute of Technology, Pasadena, CA 91125, USA.
- Department of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
ORCID-Profile: Grace C-L Jung, Frans J Walther
Förderung
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Zitieren
APA
Waring, A. J., Jung, G. C., Sharma, S. K., & Walther, F. J. (2023). Lung Surfactant Protein B Peptide Mimics Interact with the Human ACE2 Receptor. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241310837
Vancouver
Waring AJ, Jung GC, Sharma SK, Walther FJ. Lung Surfactant Protein B Peptide Mimics Interact with the Human ACE2 Receptor. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241310837
BibTeX
@article{Waring2023,
author = {Waring, Alan J and Jung, Grace C-L and Sharma, Shantanu K and Walther, Frans J},
title = {Lung Surfactant Protein B Peptide Mimics Interact with the Human ACE2 Receptor},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241310837}
}
EUVIMED